1. Scrip
  2. >>Business

India Q2 2023 Deal Trends, What May Be In Store

 
• By Anju Ghangurde

India’s healthcare and life sciences segment saw deals worth over $3bn in Q2 2023 turbocharged by private equity activity in the hospitals space and smaller biopharma acquisitions. Watch the APIs and brands space for heightened M&A action, say experts.

India Healthcare, Life Sciences Deal Values Spurt In Q2 2023 • Source: Shutterstock

India’s healthcare and life sciences segment saw a sharp jump in deal value in the second quarter of 2023, led by significant private equity interest in the hospitals space and a sprinkling of biopharma transactions, data from a report by Grant Thornton indicated.

The action in the hospitals space is expected to potentially continue, albeit at a less frenzied pace say some industry experts, while in biopharma watch out for more product/brand deals...

Max Healthcare Legal Challenge

Max Healthcare Institute Limited had earlier this year moved the Bombay High Court under section 9 of the Arbitration and Conciliation...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

More from Scrip

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback